For roughly four decades, the playbook after a heart attack has included a near-automatic prescription: beta-blockers, taken daily, often for life. The drugs became standard in the 1980s after landmark trials such as BHAT showed they cut mortality in an era before emergency stenting, powerful blood thinners, and high-dose statins existed. By some estimates, tens of millions of heart attack survivors worldwide are still on these medications. Now, four randomized controlled trials enrolling more than 10,000 patients across seven countries have converged on a conclusion that upends that routine: for survivors whose hearts still pump normally, long-term beta-blockers do not reduce death, repeat heart attacks, or hospitalizations for heart failure.
The findings, all published in the New England Journal of Medicine between 2024 and early 2025, represent the most rigorous modern test of a prescribing habit that persisted largely because no one had bothered to recheck it against contemporary care. As of June 2026, major cardiology societies are weighing how to update their recommendations, and cardiologists on both sides of the Atlantic are already rethinking which patients truly need these pills.
The trial that broke the consensus
The study drawing the most attention is REDUCE-AMI, a registry-based randomized controlled trial that enrolled 5,020 patients who had just survived a heart attack and whose left ventricular ejection fraction, the standard measure of how well the heart pumps, was 50 percent or higher. Conducted across 45 hospitals in Sweden, Estonia, and New Zealand, the trial randomly assigned participants to long-term treatment with metoprolol or bisoprolol versus no beta-blocker at all. Every patient received the full suite of modern acute care: emergency catheterization, stents, dual antiplatelet therapy, and high-intensity statins.
The primary result, published in the New England Journal of Medicine and registered as NCT03278509, was unambiguous: beta-blockers produced no meaningful reduction in the composite of death from any cause, new myocardial infarction, or hospitalization for heart failure. The hazard ratio was 0.94 with a confidence interval that comfortably crossed 1.0. In plain terms, the drug group fared no better than the group that took nothing.
Three more trials, the same answer
REDUCE-AMI did not arrive in isolation. Three additional randomized trials tested overlapping questions and reached strikingly similar conclusions.
REBOOT-CNIC, an open-label trial conducted across centers in Spain and Italy, enrolled heart attack survivors with ejection fractions above 40 percent and compared beta-blocker therapy to no beta-blocker. It found no reduction in death, reinfarction, or heart-failure hospitalization.
DANBLOCK and BETAMI, coordinated Scandinavian research programs spanning Denmark and Norway, randomized post-heart-attack patients with ejection fractions of 40 percent or higher to start a beta-blocker within 14 days or receive none. After long-term follow-up, all-cause death rates were nearly identical between the two groups.
ABYSS asked a slightly different question: what happens when patients who are already taking beta-blockers after an uncomplicated heart attack simply stop? The French trial compared interruption of chronic beta-blocker therapy against continuation and found that stopping treatment could not be declared statistically noninferior to continuing it. In practical terms, the investigators could not fully rule out a small increase in risk from discontinuation. Yet the trial also found no quality-of-life advantage to staying on the medication, a result that complicates any simple recommendation to keep prescribing.
Taken together, the four trials span Sweden, Estonia, New Zealand, Spain, Italy, Denmark, Norway, and France. Every participant received modern reperfusion therapy before randomization. Across different health systems, different beta-blocker regimens, and different study designs, the consistent signal is the same: adding a beta-blocker on top of 21st-century cardiac care does not improve hard clinical outcomes for patients whose hearts are pumping adequately.
Why the old evidence no longer holds up
The original case for beta-blockers after a heart attack was built in a fundamentally different treatment landscape. The BHAT trial, published in 1982, and the Norwegian Timolol Trial showed clear mortality benefits, but those patients did not receive emergency percutaneous coronary intervention, potent P2Y12 inhibitors like ticagrelor, or the aggressive statin regimens that are now routine. In that era, beta-blockers may have compensated for gaps in acute treatment by reducing heart rate, lowering blood pressure, and limiting the oxygen demand on damaged heart muscle.
Modern care closes many of those gaps. Rapid stenting restores blood flow within hours. Dual antiplatelet therapy prevents clot recurrence. High-intensity statins stabilize vulnerable plaques. Against that backdrop, the incremental benefit of a beta-blocker appears to have shrunk to the point of statistical invisibility, at least for patients whose hearts emerge from the event with preserved pumping function.
What the trials did not settle
Several important questions remain open. All four trials focused on patients with preserved or only mildly reduced ejection fractions. None of the published primary reports break down results by narrow ejection-fraction bands between 40 and 49 percent versus 50 percent and above. That gap matters because the precise threshold at which beta-blockers stop helping, if one exists, has not been identified. Patients with severely reduced ejection fraction or symptomatic heart failure were excluded from these studies, and the older data supporting beta-blocker use in that population remain intact. No one is suggesting those patients stop treatment based on this evidence.
Side-effect data are also thinner than many clinicians would like. Beta-blockers are well known for causing fatigue, exercise intolerance, weight gain, and sexual dysfunction. The primary trial publications do not include detailed adverse-event breakdowns that would let doctors weigh the confirmed absence of benefit against a quantified burden of harm. For patients who have tolerated the drugs without complaint, that missing data makes the stop-or-continue conversation harder.
The ABYSS result introduces its own tension. Because stopping beta-blockers failed the noninferiority test, some cardiologists interpret that as reason to continue prescribing in patients who are already stable on the medication. Others counter that the absence of any quality-of-life improvement, combined with the null findings from the other three trials, collectively weakens the case for routine lifelong use. As of mid-2026, no formal guideline update from the American Heart Association, the American College of Cardiology, or the European Society of Cardiology has resolved the disagreement, though the ESC’s 2024 guidelines already softened the recommendation for beta-blockers in this population. Clinicians are navigating a gray zone, patient by patient.
What this means for patients
The clearest takeaway is that heart attack survivors should not stop their medications on their own. The value of beta-blockers depends heavily on how well the heart is pumping and on the individual’s overall risk profile. But the days of reflexively prescribing these drugs to nearly every heart attack patient appear to be ending.
A practical way to think about the evidence is to consider three groups. Patients with clearly reduced ejection fraction or symptomatic heart failure remain strong candidates for beta-blockers; the new trials did not study them, and older data still support benefit. Patients with preserved heart function who have never started a beta-blocker after an uncomplicated heart attack now have little evidence-based reason to begin lifelong therapy solely for secondary prevention. And patients already taking beta-blockers with preserved function occupy the most uncertain ground, where the ABYSS findings, individual risk factors, and personal preferences all factor in.
Decisions about continuing, tapering, or skipping beta-blockers should be made in conversation with a treating cardiologist who can interpret these data in the context of an individual case. What the trials make clear is that the conversation itself needs to happen, because the blanket assumption that every heart attack survivor benefits from decades of beta-blocker therapy is no longer supported by the best available evidence.
Where cardiology goes from here
Subgroup analyses and longer-term safety data from these trials are still being published. If those secondary results confirm what the primary endpoints showed, guideline committees will face pressure to formally downgrade the recommendation for beta-blockers in preserved-function patients from a default prescription to an individualized decision. For health systems that have used beta-blocker prescribing rates as a quality metric after heart attacks, that shift could ripple through performance benchmarks, insurance formularies, and clinical workflows.
The broader lesson extends beyond one drug class. Medical practice sometimes outlives the evidence that created it, especially when the original trials were conducted in a treatment era that no longer exists. Reassessing long-held habits against contemporary data is not a sign that earlier doctors were wrong. It is a sign that the field has advanced enough to ask better questions and, in this case, to get answers that change the calculus for millions of people.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
